Last updated on January 2020

Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Non-Small Cell Lung Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Participants must have histologically or cytologically confirmed WT NSCLC that is stage IV / metastatic or recurrent
  2. Participants with tumor tissue high expression of PD-L1 as defined by Tumor Proportion Score (TPS) 50%
  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  4. Participants with measurable disease by spiral CT or MRI per RECIST v.1.1 criteria.
  5. Participants that have completed prior radiotherapy or radiosurgery at least 2 weeks prior to randomization.
  6. Participants must be nave to therapy for the advanced stage of the disease. Previous neoadjuvant or adjuvant therapy is allowed for participants who successfully underwent complete radical surgery and ONLY if the last treatment was administered more than 12 months prior to the start of the trial treatment

Exclusion Criteria:

  1. Participants with active central nervous system (CNS) metastases or carcinomatous meningitis
  2. Participants with any serious or uncontrolled medical disorder or active infection with the hepatitis virus or the human immunodeficiency virus (HIV)
  3. Participants with Grade 1 (NCI-CTCAE v.4.03) toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue prior to randomization
  4. Participants that have received pembrolizumab
  5. Participants with a history of severe hypersensitivity reactions to monoclonal antibodies
  6. Pregnant or lactating women
  7. Participants receiving any investigational agent within 28 days of first administration of trial treatment
  8. Participants that have received therapy with anti-tumor vaccines or other immunostimulatory antitumor agents
  9. Participants that have received therapy with anti-PD-1, anti-PD-L1, anti-PD-L-2, anti-CD-137, and/or anti CTLA-4 antibodies

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.